4D Mammography: Next-Gen Imaging Combines AI + Molecular Signatures. Calidar, Inc. has taken a major step forward in breast imaging by initiating the first in-human clinical trial of its investigational 4D Mammography system, a next-generation diagnostic tool that integrates X-ray diffraction imaging and artificial intelligence to detect disease at the molecular level. Unlike conventional mammography, which relies on density and shape to identify abnormalities, this technology measures how X-rays scatter within tissue to produce unique “molecular fingerprints.” That additional dimension of data helps distinguish between healthy and cancerous tissue with much greater precision than standard imaging alone.
In the landmark study conducted in collaboration with Baptist Health Hardin in Kentucky, Calidar successfully imaged the first patient using the system, marking the first known human application of volumetric X-ray diffraction spectral imaging. Early research indicates that this approach could significantly reduce unnecessary biopsies, improve diagnostic confidence, and shorten time to treatment; outcomes that would benefit both patients and healthcare providers. Prior ex-vivo studies showed that diffraction spectra could achieve up to four times the diagnostic precision of traditional mammograms when differentiating cancerous from benign tissue.
While the technology remains investigational and has not yet received FDA clearance, Calidar plans to expand clinical trials and explore broader applications, including earlier breast cancer screening and integration with AI-driven image interpretation. If widely adopted, such innovations could transform how clinicians detect and diagnose breast cancer and other soft tissue diseases, further illustrating the emerging role of advanced imaging systems in improving patient outcomes
Source: Calidar Announces New 4D Mammography System — Imaging Technology News